CONMED (NYSE:CNMD) Updates FY 2025 Earnings Guidance

CONMED (NYSE:CNMD) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 4.250-4.400 for the period, compared to the consensus earnings per share estimate of 4.740. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

CONMED Price Performance

Shares of NYSE:CNMD traded up $1.47 during midday trading on Wednesday, reaching $74.35. The company’s stock had a trading volume of 573,352 shares, compared to its average volume of 415,094. CONMED has a fifty-two week low of $61.05 and a fifty-two week high of $88.60. The company has a market capitalization of $2.30 billion, a P/E ratio of 17.66, a P/E/G ratio of 1.04 and a beta of 1.46. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.27 and a quick ratio of 1.06. The business’s fifty day simple moving average is $70.62 and its 200-day simple moving average is $70.19.

CONMED (NYSE:CNMD) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.14. CONMED had a return on equity of 13.84% and a net margin of 10.23%. As a group, equities research analysts expect that CONMED will post 4.03 EPS for the current fiscal year.

CONMED Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 3rd. Investors of record on Friday, December 20th were given a $0.20 dividend. The ex-dividend date of this dividend was Friday, December 20th. This represents a $0.80 dividend on an annualized basis and a yield of 1.08%. CONMED’s payout ratio is 19.00%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. StockNews.com lowered CONMED from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Needham & Company LLC restated a “buy” rating and set a $97.00 target price on shares of CONMED in a research report on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $79.80.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.